Clinical trials: Cancer Patients, open to volunteers
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC
This study is a single center, randomized controlled, prospective phase II clinical trial to evaluate the efficacy and safety of cetuximab combined with dalpicilib compared to cetuximab monotherapy in patients with HPV-negative…
- Trial name
- NCT06935188
- Testing
- Dalpicilib combined with cetuximab, cetuximab
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer
This clinical trial tests the effect of focal radiation therapy, high dose rate-brachytherapy (HDR-BT), in treating patients with prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8
- Trial name
- NCT07468903
- Testing
- Biopsy Procedure, Biospecimen Collection, High-Dose Rate Brachytherapy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Advanced Solid Tumor
Study of SGN1 in Patients With Advanced Solid Tumor
Objectives:To assess the safety and tolerability followed by a dose expansion study to characterize safety, and preliminary efficacy of SGN1 in participants with refractory solid tumors.
- Trial name
- NCT05038150
- Testing
- SGN1
- Where
- 9 sites in United States, China
- Volunteers
- 70 people
- Sponsor
- Guangzhou Sinogen Pharmaceutical Co., Ltd
Multiple Myeloma or Plasmacytoma
Engineered Dendritic Cell Vaccines for Multiple Myeloma
The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac).
- Trial name
- NCT06435910
- Testing
- DC vaccines
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Lung Cancer
Integrating Artificial Intelligence Into Lung Cancer Screening.
Lung cancer (LC) screening using low-dose chest CT (LDCT) has already proven its efficacy. The mortality reduction associated with LC screening is around 20%, much higher than the reduction in mortality associated with screening…
- Trial name
- DACAPO (NCT05704920)
- Testing
- IA, Not IA
- Where
- France
- Volunteers
- 2,722 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Lymphoma, Large B-Cell, Diffuse
Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL
A prospective, single center, randomized, clinical controlled study to evaluate the efficacy and prognosis differences between precision treatment based on plasma cfDNA testing results and the current conventional diagnostic and…
- Trial name
- NCT06289959
- Testing
- cfDNA
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Malignant Neoplasm
68Ga-JH12 PET/CT: Dosimetry and Biodistribution Study
68Ga-JH12 is a novel radiotracer targeting C-X-C motif chemokine receptor 4 (CXCR4). In this study, we observed the safety, biodistribution, and radiation dosimetry of 68Ga-JH12 in patients with different types of cancer.
- Trial name
- NCT06688188
- Testing
- 68Ga-JH12
- Where
- China
- Volunteers
- 5 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
ALK Positive, Ensartinib
A Multicenter Real-world Clinical Study on the Efficacy and Safety of Ensartinib As Neoadjuvant Treatment for Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer (NSCLC) Patients.
Explore the efficacy and safety of Ensartinib in neoadjuvant treatment for ALK-positive non-small cell lung cancer in the real world.This is a real-world study of patients receiving enshatinib-based neoadjuvant therapy with R0…
- Conditions
- ALK Positive, Ensartinib, NSCLC, Neoadjuvant Therapy
- Trial name
- NCT06736561
- Volunteers
- 100 people
- Sponsor
- Harbin Medical University
Hepatocellular Carcinoma, Hepatocellular Cancer
Patients With Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide and is frequently diagnosed at an advanced stage, resulting in limited therapeutic options.
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Liver Diseases, Liver Cancer
- Trial name
- FORCE (NCT07690683)
- Testing
- Fecal microbiota transplantation performed via colonoscopy.
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
TMB-H, Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor
The goal of this clinical trial is to determine the efficacy of IMC-001 in metastatic or locally advanced TMB-H solid tumor patients.
- Trial name
- TMB-H (NCT06365840)
- Testing
- IMC-001
- Where
- 4 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- ImmuneOncia Therapeutics Inc.
Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma
Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma
This phase II trial tests how well tafasitamab and rituximab works for the treatment of newly diagnosed follicular lymphoma. Tafasitamab is a monoclonal antibody.
- Conditions
- Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
- Trial name
- NCT07731789
- Testing
- Rituximab, Tafasitamab, Biospecimen Collection
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Washington
Prostate Cancer
Imaging Characteristics of Different ⁶⁸Ga-PSMA Probes in Prostate Cancer
This study aims to evaluate the imaging characteristics of [⁶⁸Ga]Ga-GS24-B2-250-T Injection (abbreviated as ⁶⁸Ga-GS24-B2-250-T), [⁶⁸Ga]Ga-GS24-B2-268-T Injection (abbreviated as ⁶⁸Ga-GS24-B2-268-T), [⁶⁸Ga]Ga-GS24-B2-237-T…
- Trial name
- NCT07365397
- Testing
- 68Ga-GS24-B2-268-T, 68Ga-GS24-B2-250-T, 68Ga-GS24-B2-237-T
- Volunteers
- 9 people
- Sponsor
- Shanghai Zhongshan Hospital
Cancer
A Nutrition & Exercise Prehabilitation Intervention on Inflammatory Biomarkers in AI Cancer Patients
The purpose of this study is to assess the feasibility of a prehab intervention among American Indian (AI) patients diagnosed with cancer and measure inflammatory biomarkers to evaluate the preliminary impact of the trial…
- Trial name
- NCT06644560
- Testing
- Prehabilitation Intervention
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Arizona
Brain Metastasis From Advanced HER2-negative Breast Cancer
Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis
A Prospective, multicenter, randomized controlled phase II study to evaluate the efficacy and safety of PD-L1 monoclonal antibody combined with vinorelbine + cyclophosphamide + capecitabine (VEX) metronomic chemotherapy and…
- Trial name
- NCT06839560
- Testing
- Adebrelimab+VEX Metronomic Chemotherapy+Concurrent Radiotherapy, Adebrelimab+VEX Metronomic Chemotherapy+Delayed Radiotherapy
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Liver Cancer
Development of a Risk Prediction Model for Immune-Targeted Therapy-Related Diarrhea in Patients With Hepatocellular Carcinoma Based on TCM Constitutional Types: A Prospective Cohort Study
Immune checkpoint inhibitors combined with anti-angiogenic targeted agents have become the first-line standard therapeutic regimen for advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT07741903
- Volunteers
- 500 people
- Sponsor
- Affiliated Hospital of Chengde Medical University
Cancer
A Clinical and Biological Prospective Database of Patients Treated With Anticancer Immunotherapy and Follow up of Their Immune-related Adverse Events irAE
The number of patients affected by cancer and treated with immunotherapy is continuously increasing. With the advent of these new therapies, the investigators observe the emergence of new and unexpected toxicities.
- Trial name
- IMMUCARE-BASE (NCT03989323)
- Testing
- Estimation of the incidence of the irAE
- Where
- 5 sites in France
- Volunteers
- 2,000 people
- Sponsor
- Hospices Civils de Lyon
Actinic Keratosis (AK)
An Open-Label Pharmacokinetic Study for Patients With Actinic Keratosis on the Upper Extremities or the Face
The research study will evaluate how the body absorbs and reacts to reformulated Levulan Kerastick when applied to actinic keratosis lesions (AKs) on the skin of the forearms or face followed by photodynamic therapy (PDT), a…
- Trial name
- NCT07729579
- Testing
- Investigational drug, Photodynamic therapy
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Multiple Myeloma, Fall Risk Factors
Fall Risk Assessment and an Exercise Intervention for Prevention of Falls in Multiple Myeloma Patients
Approximately one third of the population over the age of 65 falls at least once a year. The risk of falling is in increased in older patients with tumor diseases.
- Conditions
- Multiple Myeloma, Fall Risk Factors, Strength Training Effects, Balance Training Effects
- Trial name
- Myfall (NCT07044427)
- Testing
- Strength and balance training in combination with a treadmill-based pertubation intervention
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University Hospital Heidelberg
Prostate Cancer (CRPC)
Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
The goal of this clinical trial is to learn if tinengotinib combined with darolutamide or enzalutamide works to treat participants with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior androgen…
- Trial name
- NCT07871110
- Testing
- tinengotinib 10 mg QD plus darolutamide, tinengotinib 10 mg QD (2-week on / 1-week off) plus darolutamide, tinengotinib 10 mg QD plus enzalutamide
- Where
- 16 sites in China
- Volunteers
- 182 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Solid Tumor Malignancy, Breast Cancer
Ataraxis Real-World Clinical Outcomes Registry Linking AI-Based Pathology Scores to Patient Outcomes
The ARC Registry is a large-scale, multi-site, prospective, observational registry. All patients with a solid tumor malignancy who receive Ataraxis testing as part of routine clinical care are eligible for enrollment, which will…
- Trial name
- ARC (NCT07706842)
- Testing
- Ataraxis testing
- Volunteers
- 1,000 people
- Sponsor
- Ataraxis AI, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.